Keep in mind: The FDA labeling states that the software does not detect tumors for diagnosis, is informational, and does not replace manual contouring. It is limited to previously diagnosed brain metastases and requires professional finalization and modification.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain; previously diagnosed brain metastases Input: T1 post-contrast brain MRI DICOM studies in adults with known or previously diagnosed brain metastases.
Who uses it?Intended users: Qualified and trained medical professionals, including radiation-oncology professionals.
What does the software produce?Output: GTV contours and calculated tumor volumes for review, editing, and export to an external clinical platform.
What is its most important limitation?Key limitation: The FDA labeling states that the software does not detect tumors for diagnosis, is informational, and does not replace manual contouring. It is limited to previously diagnosed brain metastases and requires professional finalization and modification.
Clinical takeaway. Clinical role: Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation testing and a retrospective, blinded, multicenter study of 70 subjects and 70 MRIs evaluating the machine learning model against a reference standard established by three US board certified neuroradiologists. Lesion sensitivity was 0.90 (95% CI 0.87 - 0.94), false positive rate 0.57 lesions per MRI (95% CI 0.35 - 0.80), and DSC 0.86 (95% CI 0.83 - 0.89). Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.
The FDA labeling states that the software does not detect tumors for diagnosis, is informational, and does not replace manual contouring. It is limited to previously diagnosed brain metastases and requires professional finalization and modification.
The exact FDA document reports software verification and validation testing and a retrospective, blinded, multicenter study of 70 subjects and 70 MRIs evaluating the machine learning model against a reference standard established by three US board certified neuroradiologists. Lesion sensitivity was 0.90 (95% CI 0.87 - 0.94), false positive rate 0.57 lesions per MRI (95% CI 0.35 - 0.80), and DSC 0.86 (95% CI 0.83 - 0.89). Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance of Neosoma Brain Mets have been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing." … "Neosoma Brain Mets was evaluated in a retrospective, blinded, multicenter study. The testing dataset consisted of 70 subjects and 70 MRIs (one MRI per subject) used for the evaluation of the machine learning model performance.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and validation testing and a retrospective, blinded, multicenter study of 70 subjects and 70 MRIs evaluating the machine learning model against a reference standard established by three US board certified neuroradiologists. Lesion sensitivity was 0.90 (95% CI 0.87 - 0.94), false positive rate 0.57 lesions per MRI (95% CI 0.35 - 0.80), and DSC 0.86 (95% CI 0.83 - 0.89). Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance of Neosoma Brain Mets have been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing." … "Neosoma Brain Mets was evaluated in a retrospective, blinded, multicenter study. The testing dataset consisted of 70 subjects and 70 MRIs (one MRI per subject) used for the evaluation of the machine learning model performance.". Read from the exact FDA decision document on 2026-11-14.
Standalone lesion-level sensitivity for brain metastasis identification on 70 MRIs from 70 subjects: 0.90 (95% CI 0.87 - 0.94).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Neosoma Brain Mets was evaluated in a retrospective, blinded, multicenter study. The testing dataset consisted of 70 subjects and 70 MRIs (one MRI per subject) used for the evaluation of the machine learning model performance." … "Sensitivity rate, to assess the true positive rate of lesion identification". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K252922 FDA evidence package for Neosoma Brain Mets
DesignFDA 510(k) decision evidence and product verification for the exact submission.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
No record matched K252922 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: T1 post-contrast brain MRI DICOM studies in adults with known or previously diagnosed brain metastases.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes DICOM brain MRI input and export or use in external DICOM viewing, editing, and treatment-planning systems.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA package describes an external platform workflow; current hosting, cloud responsibility, security, availability, and local configuration remain unknown.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: GTV contours and calculated tumor volumes for review, editing, and export to an external clinical platform.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes an external platform workflow; current hosting, cloud responsibility, security, availability, and local configuration remain unknown.
Use by qualified and trained medical professionals, including radiation-oncology professionals. Follow the exact labeling, local training, supervision, and escalation requirements.
The FDA package describes an external platform workflow; current hosting, cloud responsibility, security, availability, and local configuration remain unknown.
Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The snapshot contained no PubMed or ClinicalTrials.gov candidates; no evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price or commercial contract for the exact submission and version was identified.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product payer coverage or reimbursement determination was identified in reviewed public material.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.
Authorized purpose: TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.
Authorized purpose: Prenuvo Body Composition is software that non-invasively quantifies fat, muscle, and organs from compatible MR DICOM datasets and displays internal body information, including liver and body-composition measurements, for adults age 18 and older.
Modality
MRI
Anatomy
Whole-body anatomy, liver, organs, fat, and muscle
Authorized purpose: Visualize and analyze DCE breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer, including processing, measurements, and configurable finding visualization; results are not a sole basis for patient management.
Modality
MRI
Anatomy
Breast, including biopsy-proven breast tumors/findings.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.